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Since 1990 the HIV epidemic in South Africa has had a huge 
impact on the burden of tuberculosis (TB), especially within 
poor communities where annual notification rates have risen as 
high as 1 500/100 000 population.1 Not surprisingly, as antiret-
roviral treatment (ART) clinics have been established in these 
communities, TB has emerged as a key clinical problem within 
these services. A large proportion of patients at programme 
enrolment have a history of treated TB or active TB, or develop 
TB during ART. For example, of patients entering a service 
in Gugulethu, Cape Town, 52% had a history of one or more 
previously treated episodes of TB, 25% had a diagnosis of active 
TB, and approximately 10% of patients developed TB in the first 
year of ART.2 
Patients who have TB at entry to ART programmes have 
a high mortality risk, which is twofold greater than that of 
patients who do not have TB.2 Several large studies agree 
that in multivariate analysis this excess mortality risk is not 
independently associated with TB disease activity or even 
with the fact that they have a TB diagnosis; instead high 
mortality risk is associated with these patients’ degree of 
immunodeficiency, which is typically more advanced than that 
of patients who are TB free.3-6 The fact that immunodeficiency 
appears to be the key determinant of mortality in these patients 
suggests that, in addition to antituberculosis treatment and 
co-trimoxazole prophylaxis, they should start ART without 
undue delay. However, for a long time there has been caution 
regarding early initiation of ART among TB patients in view of 
the multiple potential complications.
Factors favouring delayed ART
The key factors thought to be important in deciding the best 
time to start ART in TB patients are shown in Table I. However, 
data from a number of studies now indicate that several of the 
issues favouring delayed ART are of less importance than was 
perhaps once thought. A major concern was that concurrent 
treatment would undermine ART outcomes owing to high pill 
burdens, poor tolerability of combined multi-drug regimens, 
and pharmacokinetic drug interactions. However, in Gugule-
thu, despite the fact that over one-third of patients have over-
lapping TB treatment during their first year of ART, treatment 
compliance levels are extremely high and over 90% of patients 
maintain viral load suppression rates < 400 copies/ml at all 
follow-up time points.7 More specifically, TB patients receiving 
standard dose efavirenz-containing ART and rifampicin-con-
taining antituberculosis treatment were found to have identical 
viral load suppression rates to those without TB (both 94% < 
400 copies/ml at 48 weeks).2 Data from London also confirm 
that ART outcomes are not undermined by concurrent antitu-
berculosis treatment, irrespective of the timing of ART.8 It is 
well established that concurrent rifampicin-containing antitu-
berculosis treatment reduces plasma levels of non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) by around 30%.9,10 
However, viral load suppression rates were not impaired 
among patients in Thailand receiving standard dosages of 
efavirenz-based or nevirapine-based ART at the same time as 
rifampicin.9,10 All these data indicate that pharmacokinetic inter-
actions, high pill burden and potential intolerance of combined 
multi-drug regimens do not undermine ART outcomes to an 
appreciable extent. 
Another important concern is the risk of adverse events 
during combined treatment, especially hepatotoxicity. Many 
patients in sub-Saharan Africa receive nevirapine-based ART, 
which is well recognised to be associated with a significant risk 
of hepatotoxicity when used concurrently with rifampicin.11 
However, the risk of hepatotoxicity is much lower with 
efavirenz,12 an alternative NNRTI which is available and widely 
used in South Africa. In the ART clinic in Gugulethu, where 
monitoring of serum hepatic transaminase concentrations is 
available, no deaths due to efavirenz and rifampicin co-toxicity 
have been observed.6,13 
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Immune reconstitution disease develops in approximately 
30% of patients with TB who initiate ART,14 with the rate 
being highest for those with low CD4 cell counts initiating 
ART within the first 1 - 2 months after TB diagnosis.14 Most 
cases are mild and self-limiting, but the manifestations are 
severe in a minority of patients and occasional deaths have 
been documented at the Gugulethu clinic in Cape Town and 
elsewhere.15,16 Risk of mortality from immune reconstitution 
disease therefore remains an important variable favouring 
delayed initiation of ART.
Factors favouring early ART
The key argument favouring early initiation of ART in patients 
with TB is the risk of further HIV-associated morbidity and 
mortality. This risk was highlighted by observational stud-
ies from London, UK, which documented a high burden of 
morbidity and mortality among TB patients waiting to start 
ART.17,18 However, it is important to note that early mortality 
rates within ART programmes in resource-limited settings are 
over fourfold higher than rates among patients receiving ART 
in high-income settings, even after adjusting for the baseline de-
gree of immunodeficiency.19 Consistent with this, the mortality 
rate among South African patients preparing to start ART is ex-
ceptionally high, with the result that even short delays in ART 
initiation may be associated with considerable mortality risk 
in this setting.13,20 The risk assessment around timing of ART 
in TB patients may therefore differ between high-income and 
resource-limited settings and tip the balance further towards 
earlier ART in the latter.
Supporting this suggestion, we have analysed mortality 
among TB patients (N = 73) in the Gugulethu clinic from the 
time of programme enrolment until 4 months of ART. With a 
median delay between TB diagnosis and initiation of ART of 42 
days, we found that of 14 deaths, 10 (71%) were among patients 
waiting to start ART and only 4 (29%) occurred during ART.6 
All patients who died awaiting ART had a CD4 cell count  
< 100 cells/μl or WHO stage 4 disease. While non-randomised 
observational data are limited, these data nevertheless suggest 
that currently in this clinic the number of deaths that might be 
averted by earlier treatment far exceeds the number of deaths 
that might in any way have been caused by treatment.
Antiretroviral treatment guidelines
While international guidelines agree that ART initiation can be 
delayed in patients with TB who have CD4 cell counts > 200 
cells/μl, there is a lack of consensus regarding patients with 
CD4 cell counts < 200 cells/μl.21-24 Clearly in resource-limited 
settings, where patients typically access ART services with very 
advanced immunodeficiency, this must be a mortality-based 
decision. In the situation where an efavirenz-based (low hepato-
toxicity risk) ART regimen is used, we agree with workers else-
where25 that the decision analysis in South Africa centres around 
two key issues: the mortality risk associated with delayed ART 
versus the mortality risk from immune reconstitution disease 
with early ART. Currently, pre-ART deaths in the Gugulethu 
clinic greatly exceed those that occur during treatment, indicat-
ing the potential for mortality reduction from earlier treatment. 
The current South African Antiretroviral Treatment Guidelines 
(1st edition)26 state that ART should be delayed for 2 months 
except for patients with a CD4 cell count < 50 cells/μl or a 
‘serious HIV illness’. However, the data we have reviewed in 
this article clearly suggest that these should be revised. The 
current WHO antiretroviral treatment guidelines (2006) state 
that for patients with TB and a CD4 cell count < 200 cells/μl 
ART should be started between 2 and 8 weeks of TB treatment 
and that for those with severe immunosuppression ART 
should be started as soon as possible within this time-frame 
once antituberculosis treatment is tolerated. The data we have 
reviewed from South Africa strongly support these guidelines 
and a move towards earlier treatment, especially for patients 
with CD4 cell counts < 100 cells/μl or stage 4 disease.
Integration of TB and HIV clinical 
services
In addition to changes in treatment guidelines, much needs 
to be done to foster closer working relationships between TB 
clinics and ART services. Fifteen per cent of patients entering 
the ART clinic in Gugulethu have had TB diagnosed elsewhere 
prior to referral for ART.2 These patients arrive at the ART clinic 
having already completed a median of 3 months of antitubercu-
losis treatment despite having a median CD4 cell count of just 
66 cells/μl.6 This represents a huge delay and it is very likely 
that considerable mortality occurs among such patients before 
Table I. Factors affecting the optimal time to start antiretroviral treatment (ART) in patients with tuberculosis (TB)
Factors favouring delayed initiation of ART     Potential factors favouring early initiation of ART
Pill burden and reduced adherence      Risk of further HIV-associated morbidity
Low tolerability of combined multidrug regimens     Risk of HIV-associated mortality*
Pharmacokinetic drug interactions impairing ART outcomes   Reduced risk of TB relapse
Drug co-toxicity
Morbidity and mortality due to immune reconstitution disease*
*Factors identified as being the most important. 
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they reach the ART programme. HIV status and blood CD4 cell 
counts should be promptly assessed at TB diagnosis and, where 
appropriate, patients should be quickly referred to the ART ser-
vice. However, in Gugulethu, for example, these separate clinics 
are over a mile apart and are run separately by provincial and 
city administrations. This clearly highlights the need for close 
collaboration or integration of TB treatment and ART services. 
Conclusions
The new HIV/AIDS and sexually transmitted infections (STI) 
Strategic Plan for South Africa 2007 - 2011 offers new hope for 
the millions of South Africans who are living with HIV and 
sets important targets to improve joint management of TB and 
HIV. To enable our clinical services to provide better care for 
those with both diseases, we also suggest that the South African 
national antiretroviral treatment guidelines for use of ART in 
patients with TB should be updated to recommend earlier ini-
tiation of treatment. Moreover, stronger efforts should be made 
towards greater integration of TB and HIV treatment services. 
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